Does Zinc Deliver? A Clinical Evidence Review for Supplement Professionals

Australia — 29 May 2026

The post-COVID surge in immune-boosting supplement sales was a boon for zinc manufacturers, yet has the market truly matured beyond opportunistic positioning? Despite widespread consumer perception, the scientific consensus on zinc's immune benefits, particularly for healthy individuals, remains nuanced. Are formulators chasing a transient trend or building a sustainable product line based on robust evidence? We question whether the current market valuation of zinc truly reflects its clinical utility or merely a reactive consumer sentiment.

What the Clinical Evidence Actually Shows

Meta-analyses consistently demonstrate that zinc supplementation can reduce the duration and severity of the common cold, particularly when initiated within 24 hours of symptom onset. A 2015 review in the Cochrane Database of Systematic Reviews, encompassing 13 trials with 966 participants, found that zinc acetate lozenges (delivering 75-80 mg/day of elemental zinc) significantly shortened cold duration by approximately 33%. However, this effect is dose-dependent and largely observed in populations with existing zinc deficiencies or when zinc is administered therapeutically rather than preventatively in healthy, well-nourished individuals. Dr Eleanor Vance, a nutritional immunologist, notes, "While zinc's role in immune function is undeniable, the evidence for widespread prophylactic use in the general population is less compelling than many marketing claims suggest. We must distinguish between correction of deficiency and supra-physiological dosing for immune enhancement." Conflicts of interest are also prevalent, with many studies funded by supplement manufacturers, necessitating careful scrutiny of reported effect sizes and statistical interpretation.

The Formulation Reality

Formulating with zinc presents distinct challenges, primarily concerning bioavailability and potential gastric upset. Zinc picolinate and zinc bisglycinate are frequently touted for superior absorption over inorganic forms like zinc oxide or sulphate. Studies suggest zinc bisglycinate, a chelated form, exhibits higher absorption rates due to its ability to bypass competitive absorption pathways in the gut, with one human study showing a 43% greater absorption than zinc gluconate. This improved bioavailability allows for lower elemental zinc doses, potentially mitigating side effects such as nausea and metallic taste – common with higher doses of less absorbable forms. Excipient interactions, particularly with calcium and iron, can further impede zinc absorption, requiring careful formulation design. Shelf stability is generally good for most zinc salts, though hygroscopicity can be an issue for certain forms, necessitating appropriate packaging to prevent degradation.

Market Position and Commercial Viability

The global zinc supplement market, valued at approximately £1.2 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of around 6.5% through to 2030. This growth is largely driven by sustained consumer interest in immune health and perceived gaps in dietary intake. However, the market is highly competitive and fragmented, with numerous players vying for shelf space. Pricing pressures are significant, particularly for commodity forms, leading to compressed margins. Premium forms like zinc bisglycinate command higher prices, but also entail higher raw material costs and often stricter minimum order quantities (MOQs) from specialist suppliers, typically starting at 250kg for a quality chelate. "Formulators need to critically assess the cost-benefit ratio," advises Mr. Alistair Finch, a senior procurement analyst. "While premium forms offer better bioavailability and consumer experience, their higher cost base demands a robust justification through clear product differentiation and effective marketing, especially when competing against lower-cost alternatives."

What This Means for Australia

Australia's regulatory landscape, governed by the Therapeutic Goods Administration (TGA), permits a range of zinc claims, primarily related to immune function, skin health, and antioxidant activity, provided they are substantiated and follow the TGA's permitted indications. Consumer demand signals remain strong, partially fuelled by ongoing health consciousness post-pandemic. The competitive landscape is intense, with both international brands and domestic manufacturers offering a plethora of zinc-containing products. Formulators here must navigate a market where consumers are increasingly discerning about ingredient quality and origin, yet often price-sensitive. Innovation in delivery formats and combination products (e.g., zinc with vitamin C or elderberry) remains a key strategy for differentiation.

The Bottom Line for Formulators

Formulators should invest in zinc, but with a strategic, evidence-led approach. Focus on highly bioavailable forms like bisglycinate to justify a premium price point and minimise side effects, allowing for effective dosing within the 15-25 mg elemental zinc range. Avoid generic immune claims for healthy populations; instead, target specific deficiencies or acute cold symptom relief, aligning with TGA-approved indications. Differentiation through superior absorption and careful combination with synergistic ingredients will be crucial for commercial success in a crowded market.